MT Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MT Pharma
Largest movements
- Cash -€42,692
down €42,692 (-82.0%), from €52,035 to €9,343
mainly Investment in fixed assets (net) (-€64,447) and Debts after one year (-€44,231)
- Tangible fixed assets +€20,809
up €20,809 (+4.0%), from €520,629 to €541,438
of which Plant, machinery and equipment: +€33,951
- Receivables within one year +€18,757
up €18,757 (+70.4%), from €26,637 to €45,395
of which Trade receivables: +€25,216
- Other debts +€47,010
up €47,010 (+97.8%), from €48,073 to €95,083
- Debts after one year -€44,231
down €44,231 (-8.9%), from €498,034 to €453,803
- Profit (loss) carried forward -€33,835
down €33,835 (-62.5%), from -€54,108 to -€87,943
- Trade debts +€22,436
up €22,436 (+19.5%), from €115,166 to €137,602
- Gross operating margin +€78,953
up €78,953 (+209.5%), from €37,693 to €116,646
- Staff costs +€39,349
up €39,349 (+96.1%), from €40,966 to €80,315
- Depreciation +€18,606
up €18,606 (+64.7%), from €28,763 to €47,369
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €708,409 | €697,338 | -€11,071 | -1.6% |
| Fixed assets | 21/28 | €556,702 | €573,779 | +€17,078 | +3.1% |
| Intangible fixed assets | 21 | €36,073 | €32,341 | -€3,732 | -10.3% |
| Tangible fixed assets | 22/27 | €520,629 | €541,438 | +€20,809 | +4.0% |
| Land and buildings | 22 | €260,103 | €251,522 | -€8,581 | -3.3% |
| Plant, machinery and equipment | 23 | €242,260 | €276,211 | +€33,951 | +14.0% |
| Furniture and vehicles | 24 | €18,266 | €13,705 | -€4,561 | -25.0% |
| Current assets | 29/58 | €151,708 | €123,559 | -€28,149 | -18.6% |
| Stocks and contracts in progress | 3 | €70,935 | €66,612 | -€4,323 | -6.1% |
| Stocks | 30/36 | €70,935 | €66,612 | -€4,323 | -6.1% |
| Amounts receivable within one year | 40/41 | €26,637 | €45,395 | +€18,757 | +70.4% |
| Trade receivables | 40 | €20,179 | €45,395 | +€25,216 | +125.0% |
| Other amounts receivable | 41 | €6,459 | - | -€6,459 | |
| Cash at bank and in hand | 54/58 | €52,035 | €9,343 | -€42,692 | -82.0% |
| Deferred charges and accrued income | 490/1 | €2,100 | €2,209 | +€109 | +5.2% |
| Total equity and liabilities | 10/49 | €708,409 | €697,338 | -€11,071 | -1.6% |
| Equity | 10/15 | -€14,108 | -€47,943 | -€33,835 | -239.8% |
| Contributions | 10/11 | €40,000 | €40,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€54,108 | -€87,943 | -€33,835 | -62.5% |
| Amounts payable | 17/49 | €722,517 | €745,281 | +€22,764 | +3.2% |
| Amounts payable after more than one year | 17 | €498,034 | €453,803 | -€44,231 | -8.9% |
| Financial debts | 170/4 | €498,034 | €453,803 | -€44,231 | -8.9% |
| Amounts payable within one year | 42/48 | €224,362 | €291,478 | +€67,116 | +29.9% |
| Current portion of amounts payable after more than one year | 42 | €48,240 | €44,856 | -€3,384 | -7.0% |
| Trade debts | 44 | €115,166 | €137,602 | +€22,436 | +19.5% |
| Suppliers | 440/4 | €115,166 | €137,602 | +€22,436 | +19.5% |
| Taxes, remuneration and social security | 45 | €12,883 | €13,936 | +€1,053 | +8.2% |
| Taxes | 450/3 | €4,183 | €6,246 | +€2,062 | +49.3% |
| Remuneration and social security | 454/9 | €8,700 | €7,691 | -€1,009 | -11.6% |
| Other amounts payable | 47/48 | €48,073 | €95,083 | +€47,010 | +97.8% |
| Accrued charges and deferred income | 492/3 | €120 | - | -€120 | |
| Remuneration, social security and pensions | 62 | €40,966 | €80,315 | +€39,349 | +96.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €28,763 | €47,369 | +€18,606 | +64.7% |
| Other operating charges | 640/8 | €1,936 | €1,529 | -€407 | -21.0% |
| Gross operating margin | 9900 | €37,693 | €116,646 | +€78,953 | +209.5% |
| Operating profit (loss) | 9901 | -€33,973 | -€12,568 | +€21,405 | +63.0% |
| Financial income | 75/76B | €88 | €0 | -€87 | -99.5% |
| Recurring financial income | 75 | €88 | €0 | -€87 | -99.5% |
| Financial charges | 65/66B | €20,199 | €20,819 | +€620 | +3.1% |
| Recurring financial charges | 65 | €20,199 | €20,819 | +€620 | +3.1% |
| Profit (loss) for the period before taxes | 9903 | -€54,084 | -€33,387 | +€20,697 | +38.3% |
| Income taxes | 67/77 | €24 | €448 | +€424 | +1795.5% |
| Profit (loss) for the period | 9904 | -€54,108 | -€33,835 | +€20,273 | +37.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€54,108 | -€33,835 | +€20,273 | +37.5% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.